Mugdha Gokhale

Mugdha Gokhale

Auto-generated profile, based on publicly available information

Mugdha Gokhale

Pfizer Inc

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2014 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
MGM. Gokhale
M. Gokhale
JBJ. B. Buse
J. B. Buse
CGC. L. Gray
C. L. Gray
VPV. Pate
V. Pate
MMM. A. Marquis
M. A. Marquis
TST. Stürmer
T. Stürmer

17 January 2020 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
DRDonna R. Rivera
Donna R. Rivera
MGMugdha N. Gokhale
Mugdha N. Gokhale
MRMatthew W. Reynolds
Matthew W. Reynolds
EAElizabeth B. Andrews
Elizabeth B. Andrews
DCDanielle Chun
Danielle Chun
SRSudha R. Raman
Sudha R. Raman

11 June 2019 in JCR: Journal of Clinical Rheumatology
Verified
Journal Article
Open access
MGMugdha Gokhale
Mugdha Gokhale
CBChristopher F. Bell
Christopher F. Bell
SDScott Doyle
Scott Doyle
JFJolyon Fairburn-Beech
Jolyon Fairburn-Beech
JSJonathan Steinfeld
Jonathan Steinfeld
MDMelissa K. Van Dyke
Melissa K. Van Dyke
Objective: To estimate the prevalence and associated disease burden of eosinophilic granulomatosis with polyangiitis (EGPA) in patients with asthma from a US claims database. Methods: Two cohorts were defined using enrollees (aged ≥18 years) from the Optum deidentified Clinformatics Datamart claims database 2010–2014, based on validated EGPA case definitions with varying specificity: EGPA 1 (main cohort; more specific; patients with 2 codes [in any combination] within 12 months of each other for eosinophilia, vasculitis, or mononeuritis multiplex) and EGPA 2 (sensitivity analysis cohort; less specific; patients with 2 codes of above conditions and/or neurologic symptoms within 12 months of each other). Patients had 3 or more asthma medications in the 12-month baseline before index date (date of the second code). Eosinophilic granulomatosis with polyangiitis prevalence, asthma severity during the baseline period, oral corticosteroid (OCS) use, and health care utilization during the 12-month follow-up period were determined. Results: Overall, 88 and 604 patients were included in main cohort EGPA 1 and sensitivity analysis cohort EGPA 2, respectively; corresponding annual EGPA prevalence rates were 3.2 to 5.9 and 23.4 to 30.7 cases/million patients. Approximately 75% of patients were prescribed OCS and ~30% experienced 1 or more hospitalization; 75% in EGPA 1 and 52% in EGPA 2 with 1 or more non-OCS prescription in the 90 days before index date had severe asthma. Conclusions: Eosinophilic granulomatosis with polyangiitis prevalence estimates varied based on specificity of the case definition but were generally consistent with previous country-specific estimates. Despite differences in prevalence, both cohorts displayed a generally similar, high burden of OCS use and health care utilization, highlighting the substantial disease burden among patients with EGPA and the need for specific treatments.

14 February 2017 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
MGMugdha Gokhale
Mugdha Gokhale
JBJohn B. Buse
John B. Buse
MFMichele Jonsson Funk
Michele Jonsson Funk
JLJennifer Lund
Jennifer Lund
VPVirginia Pate
Virginia Pate
TSTil Stürmer
Til Stürmer
Aim: To compare the cardiovascular ( CV ) risk associated with dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors relative to sulphonylureas ( SUs ) and thiazolidinediones ( TZDs ). Methods: During 2007 to 2013, using M edicare data for beneficiaries aged >65 years, we identified the following 2 cohorts of new‐users, who had not been exposed to the drugs being compared in the 6 months before initiation: (1) DPP ‐4 inhibitor vs SU initiators and (2) DPP ‐4 inhibitor vs TZD initiators. Using propensity‐score‐adjusted C ox models accounting for competing risk by death, we estimated the hazard ratios ( HRs ), risk differences and 95% confidence intervals ( CIs ) for myocardial infarction ( MI ), stroke, hospitalization for heart failure ( HF ), and a combined outcome ( MI , stroke, all‐cause mortality). Results: In the DPP ‐4 inhibitor vs SU comparison, there were 30 130 DPP ‐4 inhibitor initiators and 68 382 SU initiators. Their mean age was 75 years, 41% were men and 55% had a baseline CV condition. The HR for the composite outcome was 0.75 (95% CI 0.72‐0.79) over a median treatment duration of 1 year, but the 1‐year risks of MI were 1.00 (95% CI 0.89‐1.12) and 1.47 (95% CI 1.38‐1.56) per 100 patients for DPP ‐4 inhibitors and SUs , respectively, and the corresponding stroke risks were 0.98 (95% CI 0.87‐1.10) and 1.09 (95% CI 1.01‐1.17). For the DPP ‐4 inhibitor vs TZD comparison, there were 20 596 DPP ‐4 inhibitor initiators and 13 526 TZD initiators without previous HF . Their mean age was 74 years, 42% were men and 30% had a baseline CV event. The composite outcome HR was 0.94 (95% CI 0.86‐1.02) over a median treatment duration of 1 year. The 1‐year risk for MI was ~0.90 and for stroke it was ~0.80 per 100 patients in both DPP ‐4 inhibitor and TZD initiators. Conclusion: Although limited by the short treatment period, the present study suggests there is no increased short‐term risk of MI , stroke or HF with DPP ‐4 inhibitors vs SUs / TZDs .

10 February 2016 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
MGMugdha Gokhale
Mugdha Gokhale
CGCynthia Girman
Cynthia Girman
YCYong Chen
Yong Chen
VPVirginia Pate
Virginia Pate
MFMichele Jonsson Funk
Michele Jonsson Funk
TSTil Stürmer
Til Stürmer

26 June 2018 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
MGMugdha Gokhale
Mugdha Gokhale
JBJohn B. Buse
John B. Buse
CMChristina DeFilippo Mack
Christina DeFilippo Mack
MFMichele Jonsson Funk
Michele Jonsson Funk
JLJennifer Lund
Jennifer Lund
TSTil Stürmer
Til Stürmer